| Name | Title | Contact Details |
|---|
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.
Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Our robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
PrimeGen Biotech LLC is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.